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Abstract
Defining cases of Zika virus (ZIKV) infection is a critical challenge for epidemiological
research. Due to ZIKV’s overlapping clinical features and potential immunologic cross-reac-
tivity with other flaviviruses and the current lack of an optimal ZIKV-specific diagnostic
assay, varying approaches for identifying ZIKV infections have been employed to date. This
paper presents the laboratory results and diagnostic criteria developed by the Microcephaly
Epidemic Research Group for defining cases of maternal ZIKV infection in a cohort of preg-
nant women with rash (N = 694) recruited during the declining 2015–2017 epidemic in north-
east Brazil. For this investigation, we tested maternal sera for ZIKV by quantitative reverse
transcription polymerase chain reaction (qRT-PCR), Immunoglobulin (Ig) M and IgG3
enzyme-linked immunosorbent assays (ELISAs), and Plaque Reduction Neutralization Test
(PRNT50). Overall, 23.8% of participants tested positive by qRT-PCR during pregnancy
(range of detection: 0–72 days after rash onset). However, the inter-assay concordance
was lower than expected. Among women with qRT-PCR-confirmed ZIKV and further test-
ing, only 10.1% had positive IgM tests within 90 days of rash, and only 48.5% had ZIKV-spe-
cific PRNT50 titers�20 within 1 year of rash. Given the complexity of these data, we
convened a panel of experts to propose an algorithm for identifying ZIKV infections in preg-
nancy based on all available lines of evidence. When the diagnostic algorithm was applied
to the cohort, 26.9% of participants were classified as having robust evidence of a ZIKV
infection during pregnancy, 4.0% as having moderate evidence, 13.3% as having limited
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evidence of a ZIKV infection but with uncertain timing, and 19.5% as having evidence of an
unspecified flavivirus infection before or during pregnancy. Our findings suggest that inte-
grating longitudinal data from nucleic acid and serologic testing may enhance diagnostic
sensitivity and underscore the need for an on-going dialogue regarding the optimization of
strategies for defining cases of ZIKV in research.
Author summary
On February 1, 2016, the World Health Organization declared a Public Health Emergency
of International Concern following a “cluster of microcephaly cases and other neurologi-
cal disorders in Brazil” and highlighted the “urgent need” for coordinated international
efforts to investigate the relationship between maternal Zika virus (ZIKV) infections and
microcephaly. Due to the lack of a standard algorithm, resultant epidemiological investi-
gations have utilized different strategies for defining cases of ZIKV infections in preg-
nancy. Here, we report the experience of the Microcephaly Epidemic Research Group in
Pernambuco, Brazil, in evaluating 694 pregnant women presenting with rash (i.e., a com-
mon sign of ZIKV infection) during the 2015–2017 Latin American outbreak. Integrating
time-sensitive data from both nucleic acid amplification testing and serologic assays, a
panel of experts developed an evidence-graded set of criteria for identifying cases of
maternal infection. When applied to the cohort, nearly one-third of the participants were
categorized as having robust or moderate evidence of being infected with ZIKV in preg-
nancy. The classifications described in this investigation will enable scientists to investi-
gate maternal ZIKV infection and estimate the absolute and relative risks of adverse
pregnancy outcomes. The results also underscore the importance of on-going efforts to
develop robust diagnostic assays for ZIKV.
Introduction
Defining cases is a universal challenge of epidemiological studies on Zika virus (ZIKV). This
problem is exacerbated in regions with co-circulating arthropod-borne viruses (arboviruses)
due to overlapping and often mild clinical features [1], the potential for immunologic cross-
reactivity with other flaviviruses [2–4], and the current lack of an optimal ZIKV-specific diag-
nostic assay for diagnosing recent infections [5–7]. As a consequence, different clinical and
laboratory criteria have been used to identify ZIKV exposures for the published investigations
evaluating pregnancy outcomes after maternal ZIKV infection in Brazil [8], in the French ter-
ritories of the Americas [9], and in the United States (U.S.) and their territories and freely asso-
ciated states [10, 11].
The epidemiological case definitions used to define maternal ZIKV infections in recent
studies reflect pragmatic considerations (e.g., availability and affordability of relevant diagnos-
tic tests), the recency of sample collections relative to the suspected infections (e.g., timing in
returning travelers), and the local epidemiological contexts (e.g., presence or absence of
autochthonous transmission, circulation of other flaviviruses). In the investigations by Brasil,
et al. (2016) [8] and Hoen, et al. (2018) [9], which enrolled symptomatic women from settings
with active transmission in Brazil and the French territories, it was feasible to collect biological
specimens during acute infection, and ZIKV infection in pregnancy was exclusively identified
by quantitative reverse transcription polymerase chain reaction (qRT-PCR). In contrast, in the
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studies by Reynolds, et al. (2017) [10] and Shapiro-Mendoza, et al. (2017) [11], which were
based on the U.S. Zika Pregnancy and Infant Registry, exposure was defined using combina-
tion of assays (i.e., qRT-PCR and Plaque Reduction Neutralization Test (PRNT90) for ZIKV
and immunoglobulin (Ig) M for both ZIKV and DENV) that reflected the varying time win-
dows to sample testing. Similarly, in the investigation by Pomar, et al. (2018), which enrolled
symptomatic and asymptomatic pregnant women in western French Guiana, ZIKV exposure
was laboratory-confirmed by qRT-PCR, IgM and a micro-neutralizing assay; notably, this
investigation also included subsequent IgM cord blood testing of the neonates to confirm con-
genital infection [12].
The Northeast of Brazil, including the state of Pernambuco, was the epicenter of the 2015–
2017 microcephaly epidemic associated with ZIKV infection [13]. The initial wave of ZIKV
transmission in Pernambuco occurred in the first half of 2015, and a peak of microcephaly
cases was observed among neonates born later in the same year (reviewed in [14]). In response
to this cluster of congenital abnormalities, the Brazilian Ministry of Health declared a public
health emergency [15], and epidemiological investigations into the causal factors were consid-
ered to be of paramount importance. To meet this challenge, the Microcephaly Epidemic
Research Group (MERG; http://www.cpqam.fiocruz.br/merg/) was formed in late 2015 and
rapidly launched two epidemiological investigations: a case-control study of microcephaly, for
which the results have been published [16–18], and a cohort study of pregnant women with
rash, for which analysis is on-going. In addition to confirming the link between ZIKV and
microcephaly [16, 17], the MERG case-control study demonstrated that 85% of pregnant
women participating in the Pernambuco-based study had experienced dengue virus (DENV)
infections prior to the time of their deliveries [18].
Initiating a large-scale outbreak investigation under financial constraints during a live pub-
lic health emergency introduced challenging considerations for resource mobilization and pri-
oritization in the clinical studies, and strategic decisions were made by MERG to optimize the
effectiveness of the ZIKV testing regimes. This paper presents the laboratory results and the
specific diagnostic criteria developed by MERG to define maternal infections in the cohort of
pregnant women with rash recruited in Pernambuco State, Brazil, during the declining ZIKV
epidemic. Here, we describe MERG’s methods for integrating complex longitudinal data from
qRT-PCR, IgM, IgG3, and PRNT50 assays in order to establish case definitions for ZIKV infec-
tions in pregnancy, discuss the advantages and limitations of this approach, and provide spe-
cific recommendations for future prospective cohort studies of ZIKV infections in pregnancy.
Methods
Study design and participants
Following its launch in November 2015, MERG partnered with the Pernambuco State Health
Department to develop harmonized protocols to facilitate synergistic activities between
research and surveillance. Based on these consultations, the Pernambuco State Health Depart-
ment introduced a surveillance system for pregnant women presenting with rash (Center for
Strategic Information on Health Surveillance in Pernambuco; Cievs/PE) in December 2015.
The surveillance program included no restrictions regarding the type of rash. At the time of
notification to Cievs/PE −and ideally within five days of rash onset, as recommended in the
harmonized protocols− officials from the State Health Secretariat registered women and col-
lected a first blood sample for ZIKV testing (Fig 1). MERG then invited the pregnant women
registered in Cievs/PE to participate in a prospective investigation of ZIKV infection in preg-
nancy; no exclusion criteria were applied. Initial recruitment was limited to the metropolitan
region of Recife; however, beginning in April 2016, the catchment area for recruitment was
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Fig 1. Flow diagram of molecular and serologic testing for ZIKV infection using qRT-PCR, IgM, IgG3, and PRNT50 in a cohort of pregnant women
with rash in Pernambuco, Brazil.
https://doi.org/10.1371/journal.pntd.0007763.g001
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expanded beyond Recife to include additional women with laboratory evidence for ZIKV
residing within approximately 120km of the city. MERG-associated fieldworkers collected a
second blood sample from the pregnant women (i.e., at least 14 days following initial notifica-
tion) and administered a detailed questionnaire. In cases of livebirth, a third blood sample was
collected after delivery. All blood samples were sent to the Central Laboratory of Public Health
(Recife, Pernambuco) where serum samples were separated and stored at -80˚C until further
diagnostic testing was performed at the Laboratorio de Virologia e Terapia Experimental of
the Fundac¸ão Oswaldo Cruz (LaViTE-FIOCRUZ, Recife, Pernambuco).
Laboratory procedures
The molecular and serologic diagnostic assays were performed at LaViTE-Fiocruz and have
been subject to external quality assessments within Fiocruz and international reference net-
works (e.g., see [19]). Maternal sera were tested for the detection of ZIKV genome by one-step
qRT-PCR using primers and probes previously described by Lanciotti and colleagues [4]. Spe-
cifically, the RNA was extracted automatically from human serum using a QIAmp Viral RNA
kit according to the manufacturer’s instructions (Qiagen, Hilden, Germany). The ZIKV
qRT-PCR was performed in duplicate in a final volume of 20μL with the GoTaq 1-step RT-
qPCR system according to the manufacturer’s instructions (Promega Corporation, Madison,
Wisconsin, United States of America). Cycling was performed using the QuantStudio 5 Real-
Time PCR System (ThermoFisher Scientific, Waltham, Massachusetts, United States of Amer-
ica). A standard curve for ZIKV RNA copies was prepared from a previously titrated virus
stock (range: 101 to 106 PFU/mL). Samples with a Ct value <38 in duplicate wells were consid-
ered to be positive for ZIKV. No false positives have been detected in any of the external qual-
ity assessments performed to date.
The serologic assays used in this study were selected based on their ability to discern recent
infection (i.e., IgM and IgG3) as well as their diagnostic sensitivity and specificity (i.e., PRNT).
Samples were screened for the detection of ZIKV-specific IgM antibodies by capture-IgM
enzyme-linked immunosorbent assay (ELISA) following a protocol recommended by the
United States Centers for Disease Control and Prevention (CDC, Fort Collins, Colorado,
United States of America) [20]. Results were calculated as a ratio of the average optical density
(OD) value of test sample (P) divided by the average OD value of the negative control (N).
Maternal sera were considered ZIKV-equivocal with an IgM ratio >2 and�3 and ZIKV-posi-
tive with an IgM ratio of>3. Seroconversion by IgM was considered to occur based on two
samples, with a switch from negative (i.e.,�2) to positive status (i.e.,>3). Maternal sera were
also tested for the detection of ZIKV-specific IgG3 anti-non-structural protein 1 (NS1) anti-
bodies using a novel in-house ELISA, which assessed ZIKV exposure in the past six months,
following a protocol previously described [21]. Serum samples, in duplicate, were tested in par-
allel using NS1 from ZIKV and DENV1-4 as antigens. Assay controls included: ZIKV-positive
sera from convalescent patients collected 60 days post-onset of symptoms, dengue-positive
pooled sera from early convalescent patients collected 20 to 30 days post-onset of symptoms,
and flavivirus-naïve sera (i.e., human IgG-fractionated serum purified from U.S. patients and
diluted in IgG-depleted human serum at 50mg/mL). Results were calculated as a ratio by
dividing the average OD value of the test sample by the average OD value of the dengue posi-
tive recent infection control. Maternal sera were considered ZIKV-positive with an IgG3 ratio
of>1.2. ZIKV-specific neutralizing activity was assessed in all available maternal sera by
PRNT, following a standardized protocol [22] carried out in Vero cells using a virus strain iso-
lated in the study setting (Recife, Pernambuco, Brazil): ZIKV (BR-PE243/2015) [23]. ZIKV-
specific neutralizing antibody titers were estimated using a four-parameter non-linear
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regression and expressed as the reciprocal dilution needed to achieve a 50% reduction in pla-
que counts (PRNT50). Maternal sera were considered ZIKV-non-negative with PRNT50 titers
�20, equivocal with PRNT50 titers�20 and<100, and ZIKV-positive with PRNT50 titers
�100. Seroconversion was considered to occur with four-fold rises in PRNT50 titers or with a
switch from negative (i.e., <20) to non-negative status (i.e.,�20). Subsamples of maternal sera
underwent further testing for other potential infections with TORCH agents (toxoplasmosis,
parvovirus B19, rubella, cytomegalovirus, herpes simplex virus) and other arboviruses (DENV
and Chikungunya virus).
Expert panel
A panel of experts was assembled to review the evidence and establish a case definition for the
cohort of pregnant women with rash. The experts included three virologists, one infectious
disease specialist, and one epidemiologist who were all actively engaged in the rapid response
to the 2015–2016 public health emergency in Brazil. The panel reviewed all maternal lab results
from qRT-PCR, IgM, IgG3, and PRNT50 testing in relation to the dates of the rash and the
pregnancy. Specific testing regimes varied across participating women, such that not all tests
were used for all women during each study visit. Because of this variability, the panel appraised
each woman’s test results individually. For each participant, the expert panel first considered
the qRT-PCR results in relation to the time since rash. They then examined serially evaluated
samples for evidence of seroconversion by either IgM or PRNT. Next, they considered the con-
cordance of the IgM and IgG3 results in relation to the PRNT results (i.e., evaluated in terms
of both titer and timing of testing in relation to the end of pregnancy). Finally, they considered
the individual serologic test results in the absence of any confirmatory evidence. Based on this
detailed evaluation, the panel established by consensus the specific set of rules described in this
manuscript for defining cases of ZIKV infection in pregnancy and classified women according
to the evidence-graded criteria.
Ethics statement
The study was approved by the Ethical Committee of the Instituto Aggeu Magalhães
(53240816.4.0000.5190) and was conducted in accordance with the Declaration of Helsinki,
the International Conference on Harmonisation guideline for Good Clinical Practice, and the
codes and regulations of Brazil regarding research on human subjects. Pregnant women pro-
vided a written informed consent prior to participating in the study.
Results
In coordination with this investigation, the Pernambuco State Health Department registered
707 pregnant women between December 2015 and June 2017 following a reported exanthem
(Fig 1). 694 women were recruited for further follow-up. Blood samples were collected during
the baseline visit from 70.3% (N = 488/694) of women, with a median time from symptom
onset to first blood collection of 3 (interquartile range, IQR: 1 to 6) days. During the second
study visit, fieldworkers from MERG interviewed and collected blood samples from all 694
women, with a median time to blood collection of 87 (IQR: 56 to 130) days. Second study visits
occurred prior to delivery for 50.6% (N = 351/694) of women. During the third study visit,
fieldworkers collected blood samples from 69.3% (N = 481/694) of the study sample, with a
median time to blood collection of 263.5 (IQR: 154.5 to 417.5) days. 98.8% (N = 475/481) of
third study visits occurred after the pregnancy ended. Notably, 87 women completed their
pregnancies prior to the time of blood sample collection.
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Diagnostic testing
ZIKV exposure status was evaluated in a total of 1663 serum samples collected from 364
(52.4%) women tested at 3 time points, 240 (34.6%) tested at 2 time points, and 90 (13.0%)
tested at 1 time point. Of the 1663 samples, 448 (26.9%) were evaluated by qRT-PCR, 1630
(98.0%) by IgM, 561 (33.7%) by IgG3, and 1079 (64.9%) by PRNT50. Of the 448 women whose
samples from the first study visit were tested by qRT-PCR, 127 (28.3%) were positive. Whereas
83 (82.1%) of the 101 qRT-PCR-positives with known timing were detected within 7 days of
rash onset, viral RNA was also detected in 19 (18.8%) samples collected later than one week
after rash onset (Fig 2). The latest qRT-PCR-positive sample was collected 72 days after rash
onset. Although fewer samples were collected at the later time points, the likelihood of detect-
ing viral RNA remained constant at approximately 30% for the first 28 days after the appear-
ance of the rash. Strikingly, in 73 of the 127 (57.5%) women who tested positive by qRT-PCR,
there was no confirmatory serologic evidence of infection.
Of the 694 women whose samples were tested by IgM, 71 (10.2%) were positive during at
least one time point. Similarly, of the 240 women whose samples were tested by IgG3, 20
(8.3%) were positive during at least one time point. Among the 105 women with qRT-PCR-
confirmed ZIKV and IgM testing within 90 days of rash, only 11 (10.5%) were observed to
have positive IgM tests (Fig 3). Negative test results by IgM were observed for samples col-
lected at the same time as qRT-PCR testing as well as among those collected later. Of note, pos-
itive IgM results were observed more than 90 days after rash onset in 5 women with
qRT-PCR-confirmed ZIKV at baseline. Among the 21 women with qRT-PCR-confirmed
ZIKV and IgG3 testing for ZIKV, only 1 (4.8%) was positive. Of the 581 women evaluated by
PRNT50, 324 (55.8%) had ZIKV-specific PRNT50 titers� 20 during at least one time point,
with 312 (96.3%) non-negative women exhibiting titers� 100 in at least one time point.
Among the 103 women with qRT-PCR-confirmed ZIKV and PRNT50 performed within one
year of rash, 50 (48.5%) were observed to have ZIKV-specific PRNT50 titers�20 (Fig 3).
Fig 2. ZIKV-specific qRT-PCR results in relation to time since rash onset.
https://doi.org/10.1371/journal.pntd.0007763.g002
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A subsample of 126 women who were qRT-PCR positive for ZIKV underwent further test-
ing for previous DENV infection (i.e., based on IgG antibodies). Within this group, 119 were
DENV-positive, 4 were DENV-negative, and 3 were inconclusive. Among the 93 women who
were qRT-PCR positive for ZIKV, IgG positive for DENV, and tested for ZIKV IgM within 90
days of the start of rash, 10 (10.8%) were IgM positive, 73 (78.5%) were negative, and 10
(10.7%) were inconclusive. Among the 99 women who were qRT-PCR positive for ZIKV, IgG
positive for DENV, and tested by PRNT50 within one year of the start of rash, 48 (48.5%) were
PRNT50 positive and 51 (51.5%) were PRNT50 negative. The only woman who was qRT-PCR
positive for ZIKV, IgG negative for DENV, and tested by PRNT50 within one year of the start
of rash was PRNT50 negative.
Evidence of recent ZIKV infection
Reflecting the varying degrees of confidence in the specific laboratory assays, the timing of
testing in relation to the dates of the rash and the pregnancy, and the availability of confirma-
tory test results, the expert panel developed and applied a set of definitional criteria to the data-
set. Cases were defined as having robust evidence of maternal ZIKV infection if they had a
positive nucleic acid amplification test, seroconversion, or at least two positive serologic tests
in pregnancy of if they had one positive serologic tests (i.e., IgM or IgG3) in pregnancy paired
with a non-negative PRNT50 within six months post-pregnancy (Fig 4). Cases were defined as
having moderate evidence of maternal ZIKV infection if they had only one positive serologic
test (i.e., IgM or IgG3) in pregnancy, an indication of seroconversion by PRNT50 during preg-
nancy (i.e., either a PRNT50 titer�1000 in pregnancy paired with a rise within 2 months post-
pregnancy or 4-fold rise in PRNT50 titer from pregnancy to within 2 months post-pregnancy),
or an equivocal PRNT50 test result in pregnancy paired with a positive PRNT50 within three
months post-pregnancy (Fig 5). Cases were defined as having limited evidence of ZIKV infec-
tion but with uncertain timing relative to the pregnancy if they had a positive PRNT50 in preg-
nancy or within 6 months post-pregnancy or an indication of PRNT50 seroconversion during
the 2 to 3 months post-pregnancy (Fig 6). Cases were defined as having limited evidence of a
flavivirus before or during pregnancy if they had a PRNT50 titer between 20 and 100 or a non-
negative result (i.e., unspecified titer�20) in pregnancy or within 1 month post-pregnancy
Fig 3. Among women with qRT-PCR-confirmed ZIKV, (A) ZIKV-specific IgM results within 90 days of rash onset and (B) ZIKV-specific
PRNT50 results within 1 year of rash onset.
https://doi.org/10.1371/journal.pntd.0007763.g003
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(Fig 7). Finally, cases were considered to have evidence against ZIKV infection in pregnancy if
all tests performed in pregnancy were negative (Fig 8).
Based on these criteria, 187 (26.9%) women had robust evidence of ZIKV infection in preg-
nancy (Fig 4). Within this group, 127 (67.9%) were qRT-PCR positive for ZIKV. An additional
23 (12.3%) women were observed to seroconvert in pregnancy, based on IgM test results in 8
cases and PRNT50 in 15 cases. A further 37 (19.7%) had a positive ZIKV-specific IgM or IgG3
ELISA test result coupled with a PRNT50 positive or seroconversion within 6 months post-
pregnancy.
A total of 28 (4.0%) women had moderate evidence of ZIKV infection in pregnancy (Fig 5).
Within this group, 14 (50.0%) had a positive result for ZIKV-specific IgM or ZIKV-specific
IgG3 in pregnancy. An additional 9 (32.1%) had evidence consistent with seroconversion as
indicated by PRNT50 titers� 1000 with a rising trend or a 4-fold PRNT50 titer rise, comparing
one sample collected during pregnancy with a second sample collected within 2 months post-
pregnancy. A further 5 (17.9%) were considered to have moderate evidence when PCR or
Fig 4. Robust evidence for ZIKV infection in pregnancy based on the results of qRT-PCR, IgM, IgG3, and PRNT50 in a cohort of
pregnant women with rash in Pernambuco, Brazil.
https://doi.org/10.1371/journal.pntd.0007763.g004
Fig 5. Moderate evidence for ZIKV infection in pregnancy based on the results of IgM, IgG3, and PRNT50 in a
cohort of pregnant women with rash in Pernambuco, Brazil.
https://doi.org/10.1371/journal.pntd.0007763.g005
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Fig 6. Limited evidence for a ZIKV infection before, during, or after pregnancy based on the results of IgM and PRNT50 in a cohort
of pregnant women with rash in Pernambuco, Brazil.
https://doi.org/10.1371/journal.pntd.0007763.g006
Fig 7. Limited evidence for an unspecified flavivirus infection before or during pregnancy based on the results of
PRNT50 in a cohort of pregnant women with rash in Pernambuco, Brazil.
https://doi.org/10.1371/journal.pntd.0007763.g007
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ZIKV-specific IgM results were equivocal during pregnancy and there was a positive PRNT50
for ZIKV in the three months following pregnancy.
A limited evidence outcome was reached for the 92 cases (13.3%) where a positive indicator
of infection was observed, but the timing of the infection in relation to the pregnancy could
not be firmly established (Fig 6). Within this group, 48 (52.2%) had a positive PRNT50 result
during pregnancy or within 1 month post-pregnancy. An additional 9 (9.8%) had a late
PRNT50 seroconversion, with a negative PRNT50 result in pregnancy and a positive PRNT50
between 2 and 3 months post-pregnancy. The final 35 (38.0%) had a positive PRNT50 observed
in the 2 to 6 months post-pregnancy, and it was therefore uncertain whether the ZIKV infec-
tion occurred before, during, or after the pregnancy.
Recognizing the potential for cross-reactivity in the immune responses to dengue and Zika
viruses, 135 (19.5%) women with equivocal PRNT50 results were classified as having limited
evidence of an unspecified flavivirus infection in pregnancy (Fig 7). Of these, 105 (77.8%) were
detected during pregnancy with the remaining 30 (22.2%) measured within 1 month post-
pregnancy.
Overall, 215 (31.0%) women had evidence against ZIKV infection in pregnancy (Fig 8).
Although 188 (87.4%) of this group had at least two negative tests in pregnancy, we note that
27 (12.6%) women had evidence against a ZIKV infection in pregnancy by IgM testing alone.
Finally, in the 37 (5.3% of 694) women from whom blood could not be collected prior to deliv-
ery and for whom there was no post-pregnancy evidence of ZIKV infection, there was limited
evidence against ZIKV infection in pregnancy.
Discussion
Using sera collected around the time of pregnancy from 694 women residing in a region of
Northeast Brazil with circulation of Zika and other arboviruses, we used molecular and sero-
logic assays to exhaustively test for ZIKV infections in pregnancy. Based on these test results, a
panel of experts developed a set of criteria for defining cases of ZIKV infection during preg-
nancy for epidemiological research in regions with active flavivirus transmission. These crite-
ria incorporated data from qRT-PCR, IgM, IgG3, and PRNT50 assays and aimed to account
for heterogeneity in the timing of sample collection relative to a given woman’s exanthem and
pregnancy. When applied to the cohort, 26.9% of participants were classified as having robust
evidence, 4.0% as having moderate evidence, 13.3% as having evidence of a prior ZIKV infec-
tion but with uncertain timing relative to the pregnancy, 19.5% as having evidence of a prior
Fig 8. Evidence against a ZIKV infection in pregnancy based on the results of qRT-PCR, IgM, IgG3, and PRNT50 in a cohort of pregnant women with rash
in Pernambuco, Brazil.
https://doi.org/10.1371/journal.pntd.0007763.g008
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unspecified flavivirus infection, and 31.0% as having no evidence of a ZIKV infection in
pregnancy.
The case definition described here contrasts the diagnostic strategies previously reported by
Brasil, et al. (2016) and Hoen, et al. (2018) in two key domains [8, 9]. First, MERG’s definition
is hierarchical and provides scope for women to be classified as having moderate to limited evi-
dence of a ZIKV infection. By allowing for there to be a gradation of evidence, this methodol-
ogy aimed to facilitate sensitivity analyses, to mitigate type two error, and to reduce the
potential for biased or attenuated effect estimates that could arise from misclassifications
across exposure groups. Second, this case definition relied on qRT-PCR, but also gave weight
to the results of serologic tests, in an approach that shares similarities with that described in
the CDC guidelines for clinical diagnosis [24]. A key advantage of this method is that it allows
for “catch-up” testing of women whose first study visit fell beyond the window of reliable
detection for qRT-PCR. In contrast to the U.S. Zika Pregnancy and Infant Registry investiga-
tions that rely on a “snapshot” sampling strategy [10, 11], the current method utilizes findings
from two or more time points.
Further, as recent studies have demonstrated that approximately 85% of pregnant women
in the catchment area have laboratory evidence of prior dengue infection [17, 18], adaptations
were made to the CDC guidelines for the interpretation of PRNT results (i.e., PRNT50 > 100
versus PRNT90 > 20) in order to optimize testing for the specific study context [21, 24].
The results of the laboratory testing add to the evidence base on the diagnosis of ZIKV
infections in pregnancy. Specifically, the qRT-PCR results provide important new evidence for
practitioners that there may be value in testing pregnant women by molecular methods for up
to 28 days after symptom onset. In these data, we observed a similar percentage of positive
samples collected in week 1 (26%), week 2 (34%), or weeks 3–4 (38%) after rash (Fig 2). Our
findings also indicate that a minority of qRT-PCR-positive pregnant women were observed to
have positive results when re-tested by IgM and PRNT50 assays at appropriate time intervals
during follow-up. Indeed, 73 of the qRT-PCR-positive pregnant women would have been mis-
classified as ZIKV-negative if we had instead relied exclusively on the serologic test results.
The discordance between the test results is of high public health significance. This finding
underscores the importance of rapidly collecting samples for diagnostic testing from symp-
tomatic pregnant women during periods of active ZIKV transmission. Our observation also
highlights the potential challenges the public health community faces in correctly diagnosing
women without symptoms for whom the timing of infection, and therefore the anticipated
persistence of viremia, may be less certain. Our findings regarding the low IgM sensitivity
aligns with earlier reports of travelers with previous DENV experience [2] and among the
mothers of neonates born with microcephaly during the ZIKV outbreak in northeast Brazil
[18]. Together, these results suggest IgM may be inappropriate as a first-line testing method in
regions with substantial prior flavivirus transmission. The findings from the PRNT50 assays
also raise questions about the kinetics of the ZIKV neutralizing antibody responses during
pregnancy. Consistent with previous findings from Recife that demonstrated that less than
70% of women who delivered neonates with microcephaly had detectable ZIKV-specific neu-
tralizing antibodies at the time of delivery, our study finds that fewer than 50% of the mothers
with qRT-PCR-confirmed ZIKV were found to test positive for ZIKV by PRNT50. Together,
these results suggest further research is needed to define the utility of PRNT50 as a confirma-
tory testing measure for maternal ZIKV infections.
The strengths of this study warrant consideration. As the cohort investigation was a collab-
oration between the Pernambuco State Health Secretariat and MERG, the surveillance-based
initial sampling leveraged existing local health infrastructure, thereby enabling (i) a real-time
response to epidemic conditions with first blood draws occurring at a median of 3 days after
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rash, (ii) a recruitment strategy with high geographic coverage including in economically
deprived communities, and (iii) a higher total number of women invited to participate. Fur-
ther, as there was a pre-established reference laboratory at LaViTE-FIOCRUZ (i.e., operating
since before the beginning of the ZIKV outbreak) with specific expertise in flavivirus diagnos-
tics and ready access to ZIKV-specific immunoassays and primers, there was a uniquely high
coverage rate for ZIKV testing and also an opportunity for incorporating complex methods,
such as PRNT50, and novel approaches, such as IgG3 testing, into the diagnostic criteria [25].
Finally, by incorporating a repeated sampling strategy and multiple lines of evidence, the cur-
rent approach has been designed to increase the diagnostic sensitivity and to allow for a mean-
ingful and exhaustively tested control group with evidence against ZIKV infection in
pregnancy.
On the other hand, the approach described in this study also had important limitations.
One limitation is that not all ZIKV tests were available or appropriate for all women at each of
the study visits (e.g., qRT-PCR was used almost exclusively near the time of acute rash). Simi-
larly, only a small number of women were tested for DENV IgG, which limits our ability to dis-
tinguish between women with and without a previous DENV infection. Although current
evidence suggests prior DENV exposure can influence the antibody response to ZIKV [2], we
note that approximately 95% of the women tested for DENV IgG had a positive test result,
indicating a high degree of homogeneity with respect to prior flavivirus experience across the
cohort. These results are consistent with previous publications showing a high circulation of
DENV in this area [18, 26]. Another related limitation of this study is the generalizability of
the proposed diagnostic algorithm. By design, the criteria set by MERG apply specifically to
pregnant women recruited due to exanthem who reside in active arboviral transmission set-
tings and would need to be adapted for the identification of asymptomatic ZIKV infections in
pregnancy and other epidemiologic settings. Further, the complexity and costs associated with
the described approach limit the utility of these criteria in the clinical (i.e., as opposed to
research) context, particularly in resource-limited settings or in the context of an outbreak.
Although the MERG algorithm for defining cases of ZIKV infection in pregnancy may not be
directly applicable to other study settings, these criteria set a precedent for the transparent
reporting of ZIKV case identification.
In addition, several lessons learned from this investigation are important for epidemic pre-
paredness and the planning of future investigations of ZIKV in pregnancy. Our first recom-
mendation is that future prospective cohort studies investigating ZIKV infections in
pregnancies should incorporate both nucleic acid and serologic testing platforms for defining
cases. qRT-PCR testing is highly specific and thereby mitigates the risk of misclassification that
can arise due to immunologic cross-reactivity in serologic tests. Because the window for
detecting ZIKV RNA in maternal sera is narrow, a positive result therefore provides an impor-
tant indicator of the potential gestational age of infection—a factor that may be related to the
risk of fetal abnormalities [8]. Despite these advantages, our findings indicate that relying
exclusively on nucleic acid amplification testing of maternal sera may substantially underesti-
mate the proportion of the cohort exposed. In this study, we observed that 127 women (18.3%)
tested positive by qRT-PCR, while an additional 98 (14.1%) were identified as having moder-
ate-to-robust evidence of ZIKV infection when immunologic metrics were considered.
A second recommendation is that women should be tested, if possible, prior to conception
and at more than one time during pregnancy. One advantage is that repeated testing (e.g., with
IgM across each trimester in regions without previous circulation of flaviviruses) would enable
investigators to detect cases among asymptomatic as well as symptomatic women. This will be
important in the future as the existing evidence base suggests there may be similar risks of
adverse fetal outcomes arising from symptomatic and asymptomatic maternal ZIKV infections
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[27]. Another advantage is that repeated testing with PRNT would make it feasible, in regions
with previous circulation of ZIKV, to establish seroconversion and therefore determine
whether positive results indicate an infection occurring during pregnancy or previously.
Although the persistence of ZIKV PRNT positivity remains uncertain, evidence from yellow
fever vaccination among travelers suggests that flavivirus-specific neutralizing antibodies may
remain detectable in serum for more than ten years [28]. A final advantage is that repeated
testing is likely to improve the negative predictive value of diagnostic regimes by increasing
the likelihood that samples are tested within assay-appropriate windows of detection. In our
study, integrating data from multiple tests and time points enabled us to address temporal sen-
sitivity concerns in order to gather evidence against infection and meaningfully define an
unexposed group.
Our third recommendation is that future investigations should consider testing multiple
body fluids. Although maternal sera samples were the only testing media collected during the
acute outbreak in Pernambuco state, recent case reports indicate that ZIKV may be detected
over a longer duration in other fluids including urine, saliva, vaginal secretions, and whole
blood [2, 29, 30]. For studies with a primary outcome of Congenital Zika Syndrome, it may
also be advantageous to consider testing neonatal samples (e.g., as described in [12]) in order
to establish congenital infection more directly.
Our final recommendation is that the development and optimization of diagnostic tools for
identifying ZIKV infections must be a priority for epidemic preparedness. Similar to previous
reports [2], we observed in this study that a minority of women with qRT-PCR-confirmed
ZIKV were also identified as positive by IgM and PRNT50 assays. As a first step, it will be vitally
important to prioritize studies investigating the persistence of viral replication across body
domains and the kinetics of the immune response to ZIKV, especially in vulnerable popula-
tions including pregnant women and neonates. Furthermore, due to potential immunologic
cross-reactivity, it will be valuable to validate new diagnostic tools among both populations
residing in flavivirus-endemic settings and immunologically naïve travelers.
In conclusion, this study provides a model of how complex, longitudinal nucleic acid and
serologic test results can be integrated for defining cases of ZIKV infection among pregnant
women presenting with rash. The classifications described in this investigation will enable sci-
entists to estimate the absolute and relative risks of adverse pregnancy outcomes associated
with maternal ZIKV infections and serve as a model of transparent reporting of case defini-
tions for future epidemiologic investigations conducted during outbreaks. As our understand-
ing of the pathophysiology of ZIKV infection and of the fundamental kinetics of the ZIKV-
specific immune response grows and, as new diagnostic tools are introduced, we recognize
that there is a need for an on-going dialogue regarding the optimization of strategies for defin-
ing cases in epidemiological research.
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